Retatrutide

The Triple-Agonist Mechanism

Retatrutide is studied in laboratory research as a triple-agonist research peptide — it activates the GLP-1, GIP, and glucagon receptors. This extends the dual-agonist (tirzepatide) class by adding glucagon-receptor activity, which is studied in laboratory models of energy expenditure and brown-adipose-tissue thermogenesis.

Published Phase 2 Evidence

The Phase 2 obesity trial (Jastreboff et al., New England Journal of Medicine 2023, PMID 37366315) randomized adults with obesity to retatrutide 1, 4, 8, or 12 mg weekly or placebo over 48 weeks. The 12 mg dose produced up to 24.2% mean body-weight reduction at 48 weeks, with a clear dose-response across arms. Adverse-event profile aligned with the GI-tolerability findings reported across the incretin-agonist class.

Phase 3 Status

Phase 3 outcome data for retatrutide are not yet published. The TRIUMPH program is in progress — only the protocol/design paper has been published (PMID 41090431, Diabetes, Obesity and Metabolism, January 2026). Researchers should not cite Phase 3 outcome figures until the trials report.

Research Application

Researchers investigating the triple-receptor mechanism, comparative incretin-agonist class research, or laboratory models of glucagon-receptor-mediated energy expenditure may evaluate retatrutide alongside tirzepatide (dual-agonist comparator) and semaglutide (GLP-1-only comparator). For research use only. Not for human consumption. These statements have not been evaluated by the FDA.

Science & Research

Triple-Receptor Pharmacology

GLP-1 Receptor: Retatrutide acts as a GLP-1 receptor agonist; in laboratory models, GLP-1R activation is associated with delayed gastric emptying and effects on appetite-regulatory hypothalamic pathways.

GIP Receptor: Retatrutide also activates the GIP receptor; GIP-receptor pharmacology has been studied in laboratory models of insulin secretion and hypothalamic appetite signaling.

Glucagon Receptor: The third receptor target. Glucagon-receptor activation has been studied in laboratory models of brown-adipose-tissue thermogenesis (UCP1 activation) and white-adipose-tissue lipolysis. In the triple-agonist context, the glucagon arm’s hyperglycemic potential is offset by concurrent GLP-1 / GIP activity in research models.

Pharmacokinetic Profile

Retatrutide carries a C18 fatty-diacid moiety that binds reversibly to serum albumin, extending the circulating half-life to approximately 6 days and supporting once-weekly research dosing in published pharmacokinetic studies. Pharmacokinetics are dose-proportional across the studied range (Jastreboff et al., NEJM 2023, PMID 37366315).

Published Phase 2 Clinical Evidence

Jastreboff AM et al. (2023): Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine 389(6):514–526. PMID: 37366315 · DOI: 10.1056/NEJMoa2301972. Randomized adults with obesity to retatrutide 1, 4, 8, or 12 mg weekly or placebo over 48 weeks. The 12 mg dose produced up to 24.2% mean body-weight reduction at 48 weeks. Clear dose-response across arms.

Phase 3 (TRIUMPH) Status

The Phase 3 TRIUMPH program is currently in progress. As of 2026-05-20, no Phase 3 outcome data have been published. The protocol/design paper is Diabetes, Obesity and Metabolism, January 2026, PMID 41090431. Do not cite Phase 3 outcome figures until the trials report. Sub-population research directions under investigation include MASLD (metabolic-associated steatotic liver disease), osteoarthritis, and cardiovascular endpoints.

PubMed References

• Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity (Phase 2) — NEJM 389(6):514–526. PMID 37366315.
• TRIUMPH-4 protocol/design — Diabetes, Obesity and Metabolism, January 2026. PMID 41090431.

Note: Three PMIDs previously listed in this section (34889371, 39046181, 38650651) were determined to be fabricated or misattributed during the 2026-05-20 catalog audit and have been removed.

Stacking Guide

Dual Incretin Stack (Research Comparison)

Retatrutide as Triple-Agonist Alternative to Tirzepatide

Rationale: Researchers comparing dual vs. triple agonist mechanisms often use retatrutide as the advanced alternative. The 3-4 percentage point weight loss advantage over tirzepatide derives entirely from the glucagon component’s energy expenditure enhancement. For mechanistic research comparing appetite suppression vs. energy expenditure contributions, this stack allows controlled evaluation.

Expected Research Focus: Isolating glucagon’s thermogenic contribution to total weight loss. Secondary outcomes: joint pain relief, liver function improvement, and metabolic disease research protocol beyond obesity.

Metabolic Disease Protocol

Retatrutide as Comprehensive Metabolic Therapy

Rationale: Unlike weight-loss-only compounds, retatrutide demonstrates benefits in MASLD (fatty liver disease), osteoarthritis, and cardiovascular parameters. For researchers studying metabolic disease research protocol, retatrutide offers multi-pathway efficacy through triple receptor activation.

Expected Research Focus: Hepatic metabolic improvement, inflammatory marker reduction, joint function restoration, and comprehensive metabolic syndrome research protocol through single-agent triple agonism.

Related Compounds for Comparison

Tirzepatide (dual-agonist baseline for comparative research), Cagrilintide (alternative mechanism), or semaglutide (single GLP-1 control for mechanistic studies).